A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know

Heights Capital Management recently established a new position in ImmunityBio (NASDAQ:IBRX), buying 6,565,709 shares valued at approximately $16.15 million.Heights Capital Management disclosed a new purchase of 6,565,709 ImmunityBio shares in its quarterly report filed with the U.S. Securities and Exchange Commission on November 14, 2025. The stake, valued at approximately $16.15 million at quarter-end, was not present in the previous filing and now accounts for 4.4% of the firm's reportable assets under management.This is a new position for Heights Capital Management, representing 4.4% of its $364.74 million reportable U.S. equity assets as of September 30, 2025.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool